Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate

New England Journal of Medicine

Volumn 317, Issue 15, 1987, Pages 909-916

  Stamey, Thomas A ^a,b   Yang, Norman ^a,b   Hay, Alan R ^a,b   McNeal, John E ^a,b   Freiha, Fuad S ^a,b   Redwine, Elise ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yang Laboratories ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; CLINICAL ARTICLE; DIAGNOSIS; HUMAN; MALE GENITAL SYSTEM; PROSTATE CARCINOMA; RADIOIMMUNOASSAY; TUMOR VOLUME;

EID: 0023233060     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198710083171501     Document Type: Article

References (22)

1. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159–63.
2. Graves HCB, Sensabaugh GF, Blake ET. Postcoital detection of a male-specific semen protein: application to the investigation of rape. N Engl J Med 1985; 312: 338–43.
3. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985; 76: 1899–903.
4. Watt KWK, Lee P-J, M'Timkulu T, Chan W-P, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986; 83: 3166–70.
5. Kuriyama M, Wang MC, Papsidero LD, et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980; 40: 4658–62.
6. Killian CS, Yang N, Emrich LJ, et al. Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer. Cancer Res 1985; 45: 886–91.
7. Killian CS, Emrich LJ, Vargas FP, et al. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. JNCI 1986; 76: 179–85.
8. Kuriyama M, Wang MC, Lee CL, et al. Multiple marker evaluation in prostate cancer with the use of tissue-specific antigens. JNCI 1982; 68: 99–105.
9. Pontes JE, Chu TM, Slack N, Karr J, Murphy GP. Serum prostatic antigen measurement in localized prostatic cancer: correlation with clinical course. J Urol 1982; 128: 1216–8.
10. Liedtke RJ, Batjer JD. Measurement of prostate-specific antigen by radio-immunoassay. Clin Chem 1984; 30: 649–52.
11. Shaw LM, Yang N, Brooks JJ, Neat M, Marsh E, Seamonds B. Immunochemical evaluation of the organ specificity of prostatic acid phosphatase. Clin Chem 1981; 27: 1505–12.
12. Yalow RS, Berson SA. Introduction and general considerations. In: Odell WD, Daughaday WH, eds. Principles of competitive protein-binding assays. Philadelphia: J.B. Lippincott, 1971:1–24.
13. Seamonds B, Yang N, Anderson K. Whitaker B, Shaw LM, Bollinger JR. Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers. Urology 1986; 28: 472–9.
14. Gleason DF, the Veterans Administration Cooperative Urological Research Group. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, ed. Urologic pathology: the prostate. Philadelphia: Lea & Febiger, 1977:171–98.
15. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986; 1: 60–3.
16. Mosteller F, Tukey JW. Data analysis and regression: a second course in statistics. Reading, Mass.: Addison-Wesley, 1977:93–5, 303.
17. Heller JE. Prostatic acid phosphatase: its current clinical status. J Urol 1987; 137: 1091–103.
18. Henneberry MO, Engel G, Grayhack JT. Acid phosphatase. Urol Clin North Am 1979; 6: 629–41.
19. Bates RJ, Chapman CM, Prout GR Jr, Lin C-W. Immunohistochemical identification of prostatic acid phosphatase: correlation of tumor grade with acid phosphatase distribution. J Urol 1982; 127: 574–80.
20. Ford TF, Butcher DN, Masters JRW, Parkinson MC. Immunocytochemical localisation of prostate-specific antigen; specificity and application to clinical practice. Br J Urol 1985; 57: 50–5.
21. Feiner HD, Gonzalez R. Carcinoma of the prostate with atypical immunohistological features: clinical and histologic correlates. Am J Surg Pathol 1986; 10: 765–70.
22. McNeal JE, Price HM, Redwine EA, Freiha FS, Stamey TA. Stage A versus Stage B adenocarcinoma of the prostate: morphologic comparison and biologic significance. J Urol (in press).